Entropy Neurodynamics (ASX: ENP) hits TRP-8803 trial milestone as IV psilocin approach draws patient momentum

Entropy Neurodynamics Limited (ASX: ENP), a Melbourne-based clinical-stage biotechnology company, has completed recruitment for Cohort 1 of its Phase 1 clinical trial evaluating TRP-8803, a proprietary intravenous formulation of psilocin, as a treatment for binge eating disorder. Six patients are now enrolled in the first cohort, two of whom have completed the full two-dose protocol, with the remaining four advancing through baseline assessments or approaching their first infusion. Simultaneously, Entropy Neurodynamics has begun enrolling the first two patients into Cohort 2, accelerating the trial’s timeline and signalling growing confidence in the study design. Against a market backdrop where Entropy Neurodynamics shares trade near AUD 0.033, down approximately 8% over the past year within a 52-week range of AUD 0.027 to AUD 0.046, the clinical progress announced today represents the most concrete operational milestone the company has delivered since its pipeline rebrand from Tryptamine Therapeutics in late 2025.

How does TRP-8803 differ from oral psilocybin and why does the delivery mechanism matter for clinical and commercial viability in binge eating disorder?

The distinction Entropy Neurodynamics is staking its development thesis on is not the molecule itself but how it is delivered. TRP-8803 administers psilocin, the active metabolite of psilocybin, directly via intravenous infusion rather than the oral capsule format used in most competing psychedelic therapy programs. The practical consequences of this choice are meaningful across several dimensions. First, IV administration allows clinicians to control both the onset and the depth of the psychedelic experience with a precision that oral dosing cannot replicate, since oral psilocybin must pass through the digestive system before producing a therapeutic effect and individual pharmacokinetic variability introduces uncertainty in timing and intensity.

Second, the duration of the experience under IV psilocin can be compressed relative to oral psilocybin sessions, which typically run four to six hours and impose significant staffing and facility requirements on treatment providers. A shorter, more predictable session window matters considerably for the economics of scaling psychedelic-assisted therapy into healthcare systems already strained by resource constraints. Third, precise dose titration enables the staged protocol that Entropy Neurodynamics has designed into its current trial, where Cohort 1 receives a mid-range therapeutic dose and Cohort 2 will be dosed based on optimised parameters derived from Cohort 1 outcomes. That adaptive design is less straightforward to execute with oral formulations.

What do early patient outcomes from the TRP-8803 binge eating disorder trial reveal about the drug’s therapeutic profile and potential mechanism?

The recruitment momentum Entropy Neurodynamics is reporting did not emerge from administrative efficiency alone. The company has attributed the acceleration, at least in part, to the multi-domain clinical improvements observed in the first patient treated with TRP-8803, results disclosed in an ASX announcement on 22 January 2026. That patient showed reductions in binge eating severity, improvements in depression and anxiety scores, and better body image satisfaction and overall wellbeing at the four-week post-treatment assessment. These are not independent outcomes. Binge eating disorder is heavily comorbidised with mood disorders, with estimates suggesting that nearly half of all BED patients carry at least one concurrent psychiatric diagnosis.

A therapeutic candidate that produces simultaneous improvements across eating behaviour, affective state, and self-perception within a single intervention model is addressing the condition more comprehensively than the pharmacological options currently available. Vyvanse, the only medication with specific FDA approval for binge eating disorder, operates primarily on dopaminergic pathways through its active component lisdexamfetamine and does not directly target the psychological and emotional drivers of binge episodes. That gap is precisely the space that psychedelic-assisted therapy, with its capacity to induce cognitive reappraisal and neuroplastic change, is theorised to occupy.

What is the size and structure of the binge eating disorder treatment market and where does IV psilocin fit within it?

The global binge eating disorder treatment market was valued at approximately USD 2.5 billion in 2024 and is projected to reach USD 4.8 billion by 2033, growing at a compound annual growth rate of around 7.5%. This is not a niche indication. Approximately 2.8 million adults in the United States alone are estimated to experience binge eating disorder, making it the most prevalent eating disorder in the country. The therapeutic landscape as it currently stands is dominated by cognitive behavioural therapy, antidepressants, and lisdexamfetamine. None of these options achieve remission in the majority of patients, and existing therapeutic options carry significant limitations in terms of efficacy and tolerability, creating a large unmet need for novel, more effective therapies.

Psychedelic-assisted psychotherapy is emerging as a structurally distinct approach. Where conventional pharmacotherapy manages symptoms over an extended treatment horizon, the psychedelic therapy model proposes that a small number of closely supervised sessions, combined with preparatory and integrative psychotherapy, can produce durable shifts in the patterns of cognition and behaviour that underpin the disorder. Whether TRP-8803 can deliver on that hypothesis at statistically sufficient scale is the question the current trial is designed to begin answering.

How does TRP-8803’s clinical development strategy position Entropy Neurodynamics relative to competitors in the psychedelic therapy pipeline?

Entropy Neurodynamics is not the only organisation pursuing psychedelic mechanisms in eating disorders, but it occupies a relatively defined competitive position. The company’s earlier iteration, Tryptamine Therapeutics, generated Phase 2a data using oral psilocybin across binge eating disorder, irritable bowel syndrome, and fibromyalgia. Those results informed the design of TRP-8803 and represent a meaningful advantage over programmes beginning psychedelic therapy exploration from scratch. Tryp Therapeutics reported interim results from its Phase 2 trial with psilocybin for binge eating disorder showing an average reduction of 80% in daily binge eating episodes, a result that validates the category thesis but was achieved using oral administration.

MDMA-assisted therapy developer Lykos Therapeutics received a complete response letter from the FDA in 2024, a regulatory setback that has introduced caution across the broader psychedelic therapy investment community and raised the bar for clinical package quality. Against this backdrop, Entropy Neurodynamics’ insistence on the IV delivery format and its staged dose optimisation methodology signals an intent to build a differentiated regulatory and commercial case rather than simply replicate what oral psilocybin programmes have already demonstrated.

What execution and regulatory risks remain material for TRP-8803 as Entropy Neurodynamics advances into Cohort 2?

The current trial involves 12 patients across two cohorts and is a Phase 1 study with safety and tolerability as the primary endpoint. That framing is important context for assessing how far TRP-8803 has actually progressed. This is early-stage research, and positive signals from two completed patients, however encouraging, carry limited statistical weight. The path from Cohort 1 completion to a confirmatory efficacy trial involves multiple regulatory checkpoints, additional capital requirements, and the ongoing challenge of recruiting patients for an experimental psychedelic therapy conducted under controlled clinical conditions.

Entropy Neurodynamics is a micro-cap company with a market capitalisation of approximately AUD 53 million. Its capacity to fund a Phase 2 programme that would require substantially larger patient numbers, longer follow-up periods, and potentially multi-site infrastructure will depend on the quality of data emerging from the current study and the company’s ability to attract either institutional capital or a partnership with a larger pharmaceutical organisation. The regulatory pathway for IV psilocin in binge eating disorder is also not fully established. Psilocybin and psilocin remain controlled substances in most jurisdictions, and the clinical and scheduling framework governing their therapeutic development continues to evolve in Australia, the United States, and Europe.

The company’s CEO Jason Carroll acquired one million shares on market in February 2026 at approximately AUD 0.03 per share, a AUD 30,000 commitment that signals personal conviction in the programme’s direction without constituting a material change in the company’s capital position.

What the TRP-8803 Cohort 1 milestone means for Entropy Neurodynamics investors and the binge eating disorder treatment landscape

• Entropy Neurodynamics has completed Cohort 1 recruitment for its TRP-8803 Phase 1 trial, with six patients enrolled and two having completed the full two-dose protocol, representing the most concrete clinical execution milestone the company has delivered since its rebranding from Tryptamine Therapeutics.
• TRP-8803’s intravenous psilocin delivery format offers a clinically and commercially distinct differentiation from oral psilocybin, enabling precision dose control, faster onset, and shorter session duration, each of which matters for real-world scalability in psychedelic-assisted therapy settings.
• Early patient data from the first treated individual showed multi-domain improvements including reductions in binge eating severity, depression, anxiety, and body image distress, suggesting TRP-8803 may address the psychiatric comorbidities of binge eating disorder rather than the eating behaviour alone.
• The trial’s adaptive design, where Cohort 2 dosing will be optimised based on Cohort 1 outcomes, reflects a methodologically structured approach to dose characterisation that could produce a stronger regulatory package than simpler fixed-dose studies.
• The global binge eating disorder treatment market is valued at approximately USD 2.5 billion and growing, with lisdexamfetamine remaining the only FDA-approved pharmacotherapy, leaving substantial room for a mechanism with superior psychological efficacy.
• Entropy Neurodynamics’ legacy Phase 2a oral psilocybin data from the Tryptamine Therapeutics era constitutes a meaningful competitive advantage, providing proof-of-concept evidence that informed the TRP-8803 programme design.
• Key risks remain: the trial involves only 12 patients at Phase 1 stage, the company is a micro-cap with approximately AUD 53 million market capitalisation, and capital requirements for Phase 2 development remain unfunded from the current pipeline.
• The regulatory environment for psilocin-based therapies is still evolving across all major markets, and the FDA’s handling of MDMA-assisted therapy applications in 2024 has introduced caution across the psychedelic therapy investment community.
• CEO share purchases on market in February 2026 signal insider alignment, though the quantum involved does not materially change the company’s financial position.
• Entropy Neurodynamics shares trade near AUD 0.033, close to the lower half of their 52-week range of AUD 0.027 to AUD 0.046, meaning the current price implies limited premium for clinical optionality and may represent a lag between operational progress and market pricing.